A detailed history of Us Bancorp \De\ transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 9,917 shares of BBIO stock, worth $282,932. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,917
Previous 9,597 3.33%
Holding current value
$282,932
Previous $243,000 3.7%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$23.91 - $31.3 $7,651 - $10,016
320 Added 3.33%
9,917 $252,000
Q2 2024

Aug 06, 2024

BUY
$23.0 - $31.04 $7,544 - $10,181
328 Added 3.54%
9,597 $243,000
Q1 2024

May 07, 2024

SELL
$27.35 - $40.45 $174,684 - $258,354
-6,387 Reduced 40.8%
9,269 $286,000
Q4 2023

Feb 09, 2024

SELL
$24.02 - $43.89 $122,021 - $222,961
-5,080 Reduced 24.5%
15,656 $632,000
Q3 2023

Nov 03, 2023

SELL
$16.89 - $35.01 $159,779 - $331,194
-9,460 Reduced 31.33%
20,736 $546,000
Q2 2023

Aug 09, 2023

SELL
$13.29 - $18.01 $10,698 - $14,498
-805 Reduced 2.6%
30,196 $519,000
Q1 2023

May 09, 2023

BUY
$7.17 - $18.55 $212,210 - $549,024
29,597 Added 2108.05%
31,001 $513,000
Q4 2022

Feb 13, 2023

SELL
$6.74 - $11.52 $3,754 - $6,416
-557 Reduced 28.4%
1,404 $10,000
Q3 2022

Oct 27, 2022

BUY
$7.94 - $12.36 $976 - $1,520
123 Added 6.69%
1,961 $19,000
Q2 2022

Aug 01, 2022

BUY
$5.21 - $12.14 $5,720 - $13,329
1,098 Added 148.38%
1,838 $17,000
Q1 2022

May 11, 2022

BUY
$7.34 - $17.16 $4,925 - $11,514
671 Added 972.46%
740 $8,000
Q3 2021

Nov 10, 2021

SELL
$46.87 - $64.24 $562 - $770
-12 Reduced 14.81%
69 $3,000
Q2 2021

Aug 05, 2021

BUY
$46.47 - $63.93 $1,998 - $2,748
43 Added 113.16%
81 $5,000
Q1 2021

Apr 28, 2021

BUY
$55.47 - $72.35 $2,107 - $2,749
38 New
38 $2,000

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $4.23B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.